Global T Cell Specific Surface Glycoprotein CD28 Market Trends 2025–2029: Regional Outlook and Sizing Analysis
Uncover key drivers, emerging technologies, and competitive movements shaping the t cell specific surface glycoprotein cd28 market from 2025–2034 with trusted insights from The Business Research Company
What Is The Present And Forecasted Size Of The T Cell Specific Surface Glycoprotein CD28 Market?
The T cell-specific surface glycoprotein CD28 market has experienced substantial expansion recently. Forecasts indicate a rise from $1.47 billion in 2024 to $1.62 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.1%. This historical growth is attributable to factors such as expanded research in immunotherapy, the escalating prevalence of cancer, an increase in autoimmune disease cases, a rise in clinical trials, and greater uptake of monoclonal antibodies.
The market for T cell-specific surface glycoprotein CD28 is projected to experience substantial expansion over the upcoming years. By 2029, this market is anticipated to reach a valuation of $2.35 billion, achieving a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period stems from several factors, including the escalating demand for personalized medicine, a heightened emphasis on T-cell-based therapeutic approaches, increased recognition of immuno-oncology, an expanding array of targeted therapies in development, augmented investments from pharmaceutical firms, and broader applications in the treatment of chronic diseases. Key trends defining this period involve significant progress in cell engineering technologies, sophisticated advancements in the development of bispecific antibodies, novel innovations within targeted immunotherapies, the incorporation of AI into drug discovery processes, and enhancements in biologics manufacturing.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp
What Underlying Factors Are Supporting The T Cell Specific Surface Glycoprotein CD28 Market Growth?
The market for T cell-specific surface glycoprotein CD28 is expected to grow due to the increasing emphasis on personalized medicine moving forward. Personalized medicine is a medical approach that customizes treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and enhance care. The demand for personalized medicine is on the rise, driven by advancements in genomic technologies that enable precise identification of genetic variations and the creation of tailored treatments. T cell-specific surface glycoprotein CD28 aids personalized medicine by facilitating targeted immune modulation, which results in more precise and effective therapies. It improves treatment efficacy by promoting optimal T cell activation, thereby enhancing patient-specific immune responses. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, an increase from 12 approvals in 2022. Therefore, the expanding focus on personalized medicine is propelling the growth of the T cell-specific surface glycoprotein CD28 market.
How Does The T Cell Specific Surface Glycoprotein CD28 Market Differ By Segment?
The t cell specific surface glycoprotein cd28 market covered in this report is segmented
1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types
2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry
3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers
4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research
5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories
Subsegments:
1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships
2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations
3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering
4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds
What New Opportunities Are Emerging From Trends In The T Cell Specific Surface Glycoprotein CD28 Market?
Major companies engaged in the T cell-specific surface glycoprotein CD28 market are directing their efforts towards creating innovative products, including combination immunotherapies, to improve T cell activation, anti-tumor efficacy, and patient treatment results. Combination immunotherapies are treatments that integrate multiple immune-based strategies to enhance the body’s capability to combat disease. For example, in February 2025, Rondo Therapeutics Inc., a US-based biopharmaceutical company, disclosed preclinical data concerning RNDO 564, an innovative CD28 Nectin 4 costimulatory bispecific antibody designed for advanced bladder cancer. It is specifically engineered to activate CD28 on T cells upon attachment to Nectin-4-expressing tumor cells, thereby augmenting T-cell-mediated tumor killing while reducing off-target toxicity. The data showcased strong anti-tumor activity in preclinical models, supporting its continued development as a potential therapy for patients suffering from metastatic urothelial carcinoma.
Who Are The Global Leaders Steering The T Cell Specific Surface Glycoprotein CD28 Market Forward?
Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The T Cell Specific Surface Glycoprotein CD28 Market?
North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp
Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2025, By The Business Research Company
Monitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/monitor-global-market-report
Holter Monitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report
Steam And Air Conditioning Supply Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
